Janid A. Ali
Research Subjects
Janid A. Ali has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Andrew A. Wylie
KSQ Therapeutics, Lexington, Massachusetts
25 shared publications - Andrew Olaharski
KSQ Therapeutics, Lexington, Massachusetts. 1
25 shared publications - Anne E. Dodson
Department of Genetics, Blavatnik Institute at Harvard Medical School, Boston, USA
25 shared publications - Dipen Sangurdekar
KSQ Therapeutics, Inc
25 shared publications - Edmond Chipumuro
KSQ Therapeutics, Lexington, Massachusetts
25 shared publications - Elsa Krall
KSQ Therapeutics, Lexington, Massachusetts. 1
25 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Clonogenic assays in the presence of KSQ-4279 and olaparib in combination
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Clonogenic assays in the presence of KSQ-4279 and olaparib in combination
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Mouse body weight measurements following treatment with KSQ-4279 and olaparib
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Mouse body weight measurements following treatment with KSQ-4279 and olaparib
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cell line vendor and growth media
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Cell line vendor and growth media
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Enzyme kinetic studies of KSQ-4279
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Enzyme kinetic studies of KSQ-4279
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM data collection
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
KSQ-4279 CryoEM data collection
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Combination studies using KSQ-4279 and PARP inhibitors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors
Combination studies using KSQ-4279 and PARP inhibitors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
CRISPRi system does not reduce viability of BRCA mutant cells using an intron-targeting control guide RNA (sgITC). Representative image (A) and quantification (B) of colony formation assay (treatment day 14) in MDA-MB-436 (BRCA1 mutant) cells engineered to express a DOX-inducible CRISPRi guide RNA targeting an intron (sgITC). Knockdown was validated by Western blot (representative image in C, quantification in D). FC, fold-change.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
CRISPRi system does not reduce viability of BRCA mutant cells using an intron-targeting control guide RNA (sgITC). Representative image (A) and quantification (B) of colony formation assay (treatment day 14) in MDA-MB-436 (BRCA1 mutant) cells engineered to express a DOX-inducible CRISPRi guide RNA targeting an intron (sgITC). Knockdown was validated by Western blot (representative image in C, quantification in D). FC, fold-change.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Perturbation of LIG1 induces proportional PAR accumulation in BRCA1-mutated cells in immunofluorescence and in-cell western assay formats. A) In-cell Western blotting of PAR on treatment day 4 in MDA-MB-436 cells engineered to express a DOX-inducible LIG1 cDNA with endogenous LIG1 knockout. B) Model validation with Western blotting. C) Quantification of relative NAD+ as deduced by total NAD (NADt)/NADH ratio normalized to +DOX condition (t-test sgLIG1 +DOX vs. -DOX p < 0.0001).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Perturbation of LIG1 induces proportional PAR accumulation in BRCA1-mutated cells in immunofluorescence and in-cell western assay formats. A) In-cell Western blotting of PAR on treatment day 4 in MDA-MB-436 cells engineered to express a DOX-inducible LIG1 cDNA with endogenous LIG1 knockout. B) Model validation with Western blotting. C) Quantification of relative NAD+ as deduced by total NAD (NADt)/NADH ratio normalized to +DOX condition (t-test sgLIG1 +DOX vs. -DOX p < 0.0001).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Withdrawal of Doxycycline leads to LIG1 depletion that is sustained through the study. Image (A) and quantification (B) of western blotting data from tumors of immunodeficient mice grafted with MDA-MB-436 cells engineered to express a DOX-inducible CRISPR-resistant LIG1 cDNA with endogenous LIG1 knockout. Samples depicted are from endpoint (day 29 post-grouping).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
Withdrawal of Doxycycline leads to LIG1 depletion that is sustained through the study. Image (A) and quantification (B) of western blotting data from tumors of immunodeficient mice grafted with MDA-MB-436 cells engineered to express a DOX-inducible CRISPR-resistant LIG1 cDNA with endogenous LIG1 knockout. Samples depicted are from endpoint (day 29 post-grouping).